REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Clinical trials for REFRACTORY LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cocktail aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests whether adding two antibody drugs (trastuzumab and necitumumab) to the standard pill osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib alone. About 30 participants will r…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cord blood cells engineered to fight lung cancer enter human testing
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC